The higher expression of KIF11 is also related to the higher grades of tumor clinical stage T, M, and TNM, but not with stage N. A substantial reduction in in vivo and in vitro tumor growth is recorded after KIF11 knockdown, and, interestingly, silencing of KIF11 increased the sensitivity of colon cancer cells to oxaliplatin, a common anticancer drug used in colon cancer treatment; in fact, a reduction in the IC50 value of oxaliplatin and colony formation was recorded. This evidence concerns the gene KIF11 and neoplasm.